Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator's choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)

Authors
Category Primary study
JournalAnnals of Oncology
Year 2024
This article has no abstract
Epistemonikos ID: bad6b1d1121e488b80435e200783a541d7ef7a40
First added on: Feb 19, 2025